197 related articles for article (PubMed ID: 27462066)
21. FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets.
Sun Y; Wang O; Xia W; Jiang Y; Li M; Xing X; Hu Y; Liu H; Meng X; Zhou X
J Bone Miner Metab; 2012 Jan; 30(1):78-84. PubMed ID: 21710177
[TBL] [Abstract][Full Text] [Related]
22. [Rickets/Osteomalacia. FGF23-related hypophosphatemic rickets/osteomalacia.].
Fukumoto S
Clin Calcium; 2018; 28(10):1313-1317. PubMed ID: 30269112
[TBL] [Abstract][Full Text] [Related]
23. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
24. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk.
Pastor-Arroyo EM; Gehring N; Krudewig C; Costantino S; Bettoni C; Knöpfel T; Sabrautzki S; Lorenz-Depiereux B; Pastor J; Strom TM; Hrabě de Angelis M; Camici GG; Paneni F; Wagner CA; Rubio-Aliaga I
Kidney Int; 2018 Jul; 94(1):49-59. PubMed ID: 29735309
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.
Nagata Y; Imanishi Y; Ishii A; Kurajoh M; Motoyama K; Morioka T; Naka H; Mori K; Miki T; Emoto M; Inaba M
Endocrine; 2011 Oct; 40(2):315-7. PubMed ID: 21822687
[TBL] [Abstract][Full Text] [Related]
26. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
[TBL] [Abstract][Full Text] [Related]
27. [Bone and joint diseases in children. Phosphaturic hormone, FGF23, and bone metabolism].
Ozono K
Clin Calcium; 2010 Jun; 20(6):896-903. PubMed ID: 20513948
[TBL] [Abstract][Full Text] [Related]
28. Anti-fibroblast growth factor 23 antibody therapy.
Fukumoto S
Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
[TBL] [Abstract][Full Text] [Related]
29. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
30. Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice.
Ohata Y; Yamazaki M; Kawai M; Tsugawa N; Tachikawa K; Koinuma T; Miyagawa K; Kimoto A; Nakayama M; Namba N; Yamamoto H; Okano T; Ozono K; Michigami T
J Bone Miner Res; 2014 Jul; 29(7):1627-38. PubMed ID: 24470103
[TBL] [Abstract][Full Text] [Related]
31. An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation.
Gribaa M; Younes M; Bouyacoub Y; Korbaa W; Ben Charfeddine I; Touzi M; Adala L; Mamay O; Bergaoui N; Saad A
J Bone Miner Metab; 2010; 28(1):111-5. PubMed ID: 19655082
[TBL] [Abstract][Full Text] [Related]
32. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.
Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D
Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941
[TBL] [Abstract][Full Text] [Related]
33. Hypophosphatemic rickets in opsismodysplasia.
Zeger MD; Adkins D; Fordham LA; White KE; Schoenau E; Rauch F; Loechner KJ
J Pediatr Endocrinol Metab; 2007 Jan; 20(1):79-86. PubMed ID: 17315533
[TBL] [Abstract][Full Text] [Related]
34. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.
Imel EA; Gray AK; Padgett LR; Econs MJ
Bone; 2014 Mar; 60():87-92. PubMed ID: 24325979
[TBL] [Abstract][Full Text] [Related]
35. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy.
Takashi Y; Kinoshita Y; Hori M; Ito N; Taguchi M; Fukumoto S
Endocr Res; 2017 May; 42(2):132-137. PubMed ID: 27754732
[TBL] [Abstract][Full Text] [Related]
36. [Clinical aspect of recent progress in phosphate metabolism. Treatment of hypophophatemia].
Minagawa M
Clin Calcium; 2009 Jun; 19(6):852-5. PubMed ID: 19483281
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
38. C-Terminal Fibroblast Growth Factor-23 Levels in Non-Nutritional Hypophosphatemic Rickets.
Bharati J; Bhatia D; Khandelwal P; Gupta N; Sinha A; Khadgawat R; Hari P; Bagga A
Indian J Pediatr; 2019 Jun; 86(6):555-557. PubMed ID: 30835073
[TBL] [Abstract][Full Text] [Related]
39. Vitamin D and type II sodium-dependent phosphate cotransporters.
Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K
Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552
[TBL] [Abstract][Full Text] [Related]
40. Serum fibroblast growth factor 23 is a useful marker to distinguish vitamin D-deficient rickets from hypophosphatemic rickets.
Kubota T; Kitaoka T; Miura K; Fujiwara M; Ohata Y; Miyoshi Y; Yamamoto K; Takeyari S; Yamamoto T; Namba N; Ozono K
Horm Res Paediatr; 2014; 81(4):251-7. PubMed ID: 24577200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
